Here Are 8 Essential KPIs Your Market Access Teams Should Be Looking At The route to market for any given drug is rarely a straight line. There are many obstacles to overcome and expectations are high. You need to achieve the best price and broadest possible access in the shortest possible time across the greatest […]
‘What pricing opportunities do I have when launching in a highly genericised landscape?’
‘What does differentiation look like in a crowded market place?’
The Spanish healthcare system is notorious for being cost-conscious. With COVID-19 acting as a major setback in terms of budget allocation and public debt (1), this could have consequential knock-on effects on Spain’s willingness to pay for drugs.
As we welcome our 6th director to Access Infinity and take our collective market access experience to well over a century, we have been thinking about what sets us apart as a market access consultancy.
Generating comprehensive data in rare diseases or chronic progressive conditions, can be challenging often requiring lengthy study durations and very high investment. The European Medicines Agency (EMA) therefore considers granting early market authorisation of a product for seriously debilitating, life-threatening, or rare diseases. Given the current global climate from challenges posed by COVID-19, even more interest has […]
‘What pricing opportunities do I have when launching in a highly genericised landscape?’
‘What does differentiation look like in a crowded market place?’
